Inotiv Inc (NOTV) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Inotiv Inc stock (NOTV) is currently trading at $0.30. Inotiv Inc PS ratio (Price-to-Sales) is 0.02. Analyst consensus price target for NOTV is $3.25. WallStSmart rates NOTV as Sell.
- NOTV PE ratio analysis and historical PE chart
- NOTV PS ratio (Price-to-Sales) history and trend
- NOTV intrinsic value — DCF, Graham Number, EPV models
- NOTV stock price prediction 2025 2026 2027 2028 2029 2030
- NOTV fair value vs current price
- NOTV insider transactions and insider buying
- Is NOTV undervalued or overvalued?
- Inotiv Inc financial analysis — revenue, earnings, cash flow
- NOTV Piotroski F-Score and Altman Z-Score
- NOTV analyst price target and Smart Rating
Inotiv Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Inotiv Inc (NOTV) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Inotiv Inc (NOTV) Key Strengths (2)
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
Inotiv Inc (NOTV) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Revenue growing slowly at 0.80% annually
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Inotiv Inc (NOTV) Detailed Analysis Report
Overall Assessment
This company scores 32/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Price/Book. Valuation metrics including Price/Sales (0.02), Price/Book (0.09) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Growth concerns include Revenue Growth at 0.80%, which may limit upside. Profitability pressure is visible in Return on Equity at -49.80%, Operating Margin at -13.40%, Profit Margin at -13.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -49.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 0.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NOTV Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
NOTV's Price-to-Sales ratio of 0.02x trades at a deep discount to its historical average of 2.45x (1th percentile). The current valuation is 100% below its historical high of 6.7x set in Dec 2007, and 9% above its historical low of 0.02x in Mar 2026. Over the past 12 months, the PS ratio has expanded from ~0.0x, reflecting growing market expectations outpacing revenue growth.
Compare NOTV with Competitors
Top DIAGNOSTICS & RESEARCH stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Inotiv Inc (NOTV) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
Inotiv Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 514M with 80% growth year-over-year. The company is currently unprofitable, posting a -13.5% profit margin.
Key Findings
Revenue growing at 80% YoY, reaching 514M. This pace significantly outperforms most DIAGNOSTICS & RESEARCH peers.
The company is unprofitable with a -13.5% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -11M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Inotiv Inc maintain 80%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 4.22, so expect amplified moves relative to the broader market.
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact Inotiv Inc.
Bottom Line
Inotiv Inc is a high-conviction growth story with revenue accelerating at 80% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -13.5% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Inotiv Inc(NOTV)
NASDAQ
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. The company is headquartered in West Lafayette, Indiana.